David W. Henry

David Henry
  • Associate Professor Emeritus
  • Department of Pharmacy Practice

Contact Info

School of Pharmacy, Room 2001H
2010 Becker Dr.
Lawrence, KS 66047-1620
KU Medical Center, Room Wescoe 6020A
3901 Rainbow Blvd., MS 4047
Kansas City, KS


Former Department of Pharmacy Practice Chair David Henry received his BS in pharmacy and MS in hospital pharmacy administration from KU. He became interim chair of the Department of Pharmacy Practice in November, 2010, and chair in May, 2011.

He was named a fellow in the American Society of Health-System Pharmacists in 1993 and became a board-certified oncology pharmacist in 1998. His clinical specialty since 1986 has been pediatric hematology/oncology, working with the KU Hospital PHO team.

Henry has been very active in the Pediatric Oncology Group (1991) and subsequently the Children’s Oncology Group (2000) for more than 20 years, and much of his scholarly activity has been through this association. He has also been active in ASHP, AACP, and HOPA.


M.S. in Hospital Pharmacy Administration, University of Kansas, Lawrence, KS
B.S. in Pharmacy, University of Kansas, Lawrence, KS


Courses Taught

  • PHPR 502 (OTC’s)
  • PHPR 646 (Oncology Therapeutics)
  • PHPR 508 (Oncology Pharmacy Elective, Coordinator)

Additional lectures in:

  • PHCH (Clinical Pharmacokinetics)
  • PHCH 667 (Intro to Clinical Laboratory)


  • Pediatric Hematology/Oncology

Selected Publications

Burke, E. Rockey, M. Grauer, D. & Henry, D. (2017). Assessment of cetuximab-induced infusion reactions and administration rechallenge at an academic medical center. Medical Oncology, 34, 51. DOI:10.1007/s12032-017-0902-9

Williams, K. Grauer, D. Henry, D. & Rockey, M. (2017). Corticosteroidsfor the management of immune-related adverse events in patients receiving checkpoint inhibitors. J Oncol Pharm Practice. DOI:10.1177/1078155217744872

Henry, D. W., & Kaiser, N. (2017). Pediatric malignancies. In C. S Zeind, C. G Michael, & et al. (Eds.), Applied Therapeutics: The Clinical Use of Drugs. (11th editionth ed.) (pp. Chpt 95). Wolters Kluwer.

Narveson, L. Kathol, E. Rockey, M. & Henry, D. (2016). Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease. Medical Oncology, 33(10), 107. DOI:10.1007/s12032-016-0822-0

Skapek SX, Anderson JR, Hill DA, Henry D., et al. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children’s Oncology Group (COG) phase II study. Pediatr Blood Cancer 2012;   DOI 10.1002/pbc.24457

Felgenhauer JL, Nieder ML, Grailo MD, Bernstein ML, Henry D.W., et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic ewing sarcoma family of tumors: A Children’s Oncology Group (COG) phase II study NCT00061893. Pediatr Blood Cancer 2012; Oct 12. doi:10.1002/pbc.24328 (Epub ahead of print)

Henry D.W., Holdsworth MT, Kaiser NA. Pediatric Malignancies. In Koda-Kimble MA, Young LY, Alldredge BK, et al. Applied Therapeutics: The Clinical Use of Drugs. Lippincott, Williams & Wilkins. Philadelphia. 10th edition. 2012. pp. 2143-2171

Lee A, Henry D.W., Ng JS, Parsons K, Poon BB, Schwartz J, Smith T, Assanasen C. Ifosfamide neurotoxicity in pediatric patients: a multi-institutional case series report, J Hematol Oncol Pharm 2011;1:12-17

Kettle JK, Grauer D, Folker TL, O’Neal N, Henry D.W., Williams CB. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy,  Pharmacotherapy 2010;30:812-17 (Won HOPA Literature Award in 2011 for Dr. Kettle)

Cohen MS, Al-kasspooles MF, Williamson SK, Henry D., Broward M, Roby KF. Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo, Ann Surg Oncol 2010;17(1):296.  (DOI 10.1245/s10434-009-0669-0, Online 26 Aug 2009)

Selected Presentations

  • “Pharmacists and the Healthcare Team” Community Health Program (interprofessional student summer experience and research program, University of Kansas Medical Center) June 27, 2012
  • “Pediatric Ewing Sarcoma: Dose-Dense Therapy” 7th Annual HOPA meeting, Salt Lake City, UT, March 23, 2011
  • “Chemotherapy-induced Nausea and Vomiting: Antiemetic Agents” Cancer Center Staff at Stormont Vail Hospital, Topeka, KS, May 25, 2010
  •  “Issues in Dosing Chemotherapy” Hematology Oncology Pharmacy Association, 5th Annual Meeting, June, 2009, Miami, FL
  • “Emerging toxicities in Pediatric Oncology” Hematology Oncology Pharmacy Association, 3rd Annual Meeting, June 16, 2007, Denver, CO

Awards & Honors

  • Kansas Council of Health-System Pharmacists Legacy Award, 2012
  • Harold N. Godwin Leadership Legacy Award, 2009
  • Preceptor of the Year, KU School of Pharmacy, (2001-2002, 2002-2003, 2006-2007, 2011-2012, selected by graduating students)


  • Nominations and Awards Committee, Hematology and Oncology Pharmacists Association, (Vice-chair, 2011, 2012)
  • Kappa Psi, Rho chapter, University of Kansas School of Pharmacy, Grand Council Deputy (Advisor, 2001- present)
  • Student Society of Health-System Pharmacists (Advisor, 2007-present)
  • ASHP “Student Forum” faculty liaison to the University of Kansas School of Pharmacy, (1986-2001, 2007- present)
  • Liaison to Kansas Council of Health-System Pharmacists, (2010–present)
  • Specialty Council on Oncology Pharmacy, Board of Pharmaceutical Specialties, 2006–2011. (Chair, 2010 and 2011)
  • Pharmacy Committee Core Committee, Children’s Oncology Group, (2001-2010)
  • Core committee of the Nutrition subcommittee of Cancer Control, Children’s Oncology Group, (2005- 2010)
  • Group Chair’s Protocol Review Committee, Children’s Oncology Group, (2005- 2008)